Description
Description: Erlonat, containing the active substance erlotinib, is a medication manufactured by Natco Pharma Ltd. It is a targeted therapy used in the treatment of certain types of cancer, particularly non-small cell lung cancer (NSCLC) and pancreatic cancer. Erlotinib is classified as a tyrosine kinase inhibitor, specifically targeting the epidermal growth factor receptor (EGFR), which is often overexpressed in cancer cells.
Active Substance: Erlotinib is the active substance in Erlonat. It belongs to the class of tyrosine kinase inhibitors, which work by inhibiting specific enzymes involved in cell signaling pathways that promote cancer cell growth and proliferation. By targeting the EGFR, erlotinib helps to block the signaling pathways that contribute to tumor growth and progression.
Form: Erlonat is available in the form of tablets, with each tablet containing 100 mg of erlotinib. The medication is typically supplied in blister packs containing 30 tablets, providing a standardized and convenient dosage regimen.
Manufacturer: Erlonat is manufactured by Natco Pharma Ltd., a reputable pharmaceutical company known for its commitment to producing high-quality and affordable medications. Natco Pharma Ltd. adheres to stringent quality control measures and regulatory standards to ensure the safety, efficacy, and consistency of its products.
Erlonat is commonly prescribed by healthcare professionals as a targeted therapy for patients with advanced or metastatic non-small cell lung cancer (NSCLC) or pancreatic cancer. It is typically administered orally once daily, with or without food. Dosage may vary depending on individual patient factors and response to treatment. Regular monitoring and follow-up with a healthcare provider are essential for the management of potential side effects and assessment of treatment efficacy.
Reviews
There are no reviews yet.